TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03307512
Drug: Insulin Lispro (Humalog U-100)
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
Study: NCT03982862
Drug: Botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 4U Botox® diluted to 0.1 ml
Study: NCT01953783
Drug: IXAZOMIB
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part A: Ixazomib 4.1 mg containing approximately 500-nCi \[14C\]-ixazomib, solution, orally on Day 1 and ixazomib 4 mg, capsule, orally on Days 14 and 21.~Part B: Ixazomib 4 mg, capsule, orally, once weekly, on Days 1, 8 and 15 in 28-day cycles until disease progression or unacceptable toxicity.
Study: NCT03031535
Drug: Intranasal octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal spray of octreotide acetate
Study: NCT03031535
Drug: Subcutaneous octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injectable solution of octreotide acetate
Study: NCT01789281
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus was provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. The starting dose of everolimus was the same as the last dose that was given in the parent study. Dose modification thereafter was done at the discretion of the Investigator based upon what is in the subject's best interest.
Study: NCT01789281
Drug: Sandostatin LAR Depot
Normalized name: SandoSTATIN LAR Depot
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sandostatin LAR Depot was provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections was the same as the last dose that was given in the parent study.
Study: NCT00289484
Drug: Omega-3 Polyunsaturated Fatty Acids
Normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04343729
Drug: Methylprednisolone Sodium Succinate
Normalized name: Methylprednisolone Sodium Succinate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: injectable solution at a dose of 0.5mg/kg
Study: NCT01459237
Drug: Acthrel
Normalized name: Acthrel
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine Corticorelin
Study: NCT03300960
Drug: Ganirelix (GnRH antagonist)
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
Study: NCT00455767
Drug: EPI-hNE4
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
Study: NCT00760214
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
Study: NCT00760214
Drug: Azilsartan medoxomil
Normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
Study: NCT00760214
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
Study: NCT00700570
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5mg/kg iv on day 1 of each 2 week cycle.
Study: NCT00700570
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m2 iv on day 1 of each 2 week cycle
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 0.3 mg, Once daily, once
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 1.5 mg, Once daily, once
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 5.0 mg, Once daily, once
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 15.0 mg, Once daily, once
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 50 mg, Once daily, once
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 100 mg, Once daily, once
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 200 mg, Once daily, once
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 400 mg, Once daily, once
Study: NCT03119064
Drug: Nanoliposomal Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, Oral, 50 mg, Once daily, once
Study: NCT01454115
Drug: BMS-708163 (Gamma-Secretase Inhibitor)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Solution, Oral, 800 mg, Once daily, once
Study: NCT00150540
Drug: Lanthanum carbonate
Normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02180269
Drug: JNJ-54861911 (25 mg)
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of JNJ-54861911, 25 mg on Day 1.
Study: NCT02180269
Drug: JNJ-54861911 (50 mg)
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of JNJ-54861911, 50 mg on Day 1.
Study: NCT02180269
Drug: JNJ-54861911 (100 mg)
Normalized name: JNJ-54861911
DrugBank: Atabecestat (DB15307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of JNJ-54861911, 100 mg on Day 1.
Study: NCT03432312
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine mint lozenge, 4 mg
Study: NCT03432312
Drug: Nicotine lozenge
Normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NiQuitin mint lozenge, 4 mg
Study: NCT02040285
Drug: Bisacodyl & PEG-CS
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the day before the CTC:~* low fiber diet~* at 15.00: 2 tablets of bisacodyl (5 mg)~* at 17.00: 1 litre of PEG-CS~* liquid diet~the day of the exam:~* at home: 2 tablets of bisacodyl (5 mg)~* at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water~* at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im
Study: NCT02040285
Drug: Iopamidol
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: the day before CTC:~* low fiber diet~* at 15.00: 90 ml of Iopamidol in 250 ml of water~* at 17.00: 90 ml of Iopamidol in 250 ml of water~* at 20.00: start liquid diet
Study: NCT02097043
Drug: DA-7218
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00736879
Drug: Dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, Oral, Once Daily, Up to 24 weeks
Study: NCT05032248
Drug: Tacrolimus ointment
Normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral gel
Study: NCT00931736
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
Study: NCT00931736
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and \< 50 kg, otherwise 300 mg for those weighing \< 36 kg. Total duration of treatment is for 4 months.
Study: NCT02088242
Drug: Astaxanthin
Normalized name: Astaxanthin
DrugBank: Astaxanthin (DB06543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
Study: NCT00089856
Drug: Chemotherapy (Taxotere and prednisone)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (Taxotere and prednisone)
Study: NCT02943460
Drug: Cilofexor
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily with food
Study: NCT02943460
Drug: Placebo to match cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet(s) administered orally once daily with food
Study: NCT03119064
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
Study: NCT00602550
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01677455
Drug: ganetespib
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
Study: NCT01068652
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
Study: NCT01068652
Drug: insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
Study: NCT02608320
Drug: Duragesic (Fentanyl Transdermal System [TDS] Small Patches)
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study: NCT01068652
Drug: biphasic insulin aspart 30
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
Study: NCT01068652
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000-2000 mg/day in combination with insulin treatment
Study: NCT00267189
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
Study: NCT02608320
Drug: Duragesic (Fentanyl TDS Large Patches)
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
Study: NCT00783965
Drug: tazarotene
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied to the skin
Study: NCT00365144
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01439568
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT01439568
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT04459273
Drug: Gallium Ga 68 FAPi-46
Normalized name: Gallium Ga 68 FAPi-46
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT02169973
Drug: JNJ-42165279
Normalized name: JNJ-42165279
DrugBank: JNJ-42165279 (DB15173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
Study: NCT02169973
Drug: 11C-MK-3168
Normalized name: 11C-choline
DrugBank: Choline C 11 (DB09277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
Study: NCT03248843
Drug: KN035
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
Study: NCT02608320
Drug: Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)
Normalized name: JNJ-63839880-AAA
DrugBank: MVA-mBN226B (DB17780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
Study: NCT02593201
Drug: Extended antibiotics (cefazolin or ceftazidime)
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To continue with the existing effective antibiotic therapy for one extra week
Study: NCT02593201
Drug: Usual antibiotics (cefazolin or ceftazidime)
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual duration of effective antibiotic therapy therapy
Study: NCT02430350
Drug: Compound Edaravone Injection
Normalized name: edaravone Injection
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02430350
Drug: Edaravone Injection
Normalized name: edaravone Injection
DrugBank: Edaravone (DB12243)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00760448
Drug: insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01632137
Drug: Rebamipide 2% ophthalmic suspension
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Instill one drop into each eye 4 times a day for 4 weeks.
Study: NCT01062048
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
Study: NCT03282851
Drug: US-licensed Actemra
Normalized name: Actemra
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive a single injection of US-licensed actemra on Day 1.
Study: NCT03282851
Drug: EU-approved RoActemra
Normalized name: Actemra
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive a single injection of EU-approved RoActemra on Day 1.
Study: NCT03970213
Drug: Tranexamic Acid 100Mg/Ml Inj Vil 10Ml
Normalized name: TRANEXAMIC ACID 100MG/ML INJ VIL 10ML
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV TXA given during surgery
Study: NCT01926665
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
Study: NCT01926665
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
Study: NCT03773211
Drug: Renaparin
Normalized name: reviparin
DrugBank: Reviparin (DB09259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL added at one occasion ex-vivo to machine perfusion solution to treat kidney at least 3 hours prior to transplantation
Study: NCT01248481
Drug: Acarbose (Glucobay, BAYG5421)
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
Study: NCT00234234
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02410655
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
Study: NCT02410655
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
Study: NCT00143065
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m2/day for 5 days every 28 days (Week 2,6,10,14, 18,and 22) will be administered by IV over 10-30 minutes. (Fludarabine should be given AFTER rituximab on all days on which both drugs will be administered.)
Study: NCT00143065
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Day 1, week 2 of cycle 1 rituximab 100 mg will be administered by IV, without dose escalation, over 4 hours (rate: 25 mg/hr). Day 3, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 50 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* On Day 5, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 100 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.~* Rituximab 375 mg/m2 will be repeated on Day 1 of Week 6, 10, 14, 18, and 22. During these treatments, acetaminophen and diphenhydramine prophylactic treatment is left to the discretion of the treating physician.